 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
|
Articles 
Jeremy D. Kark, Jacob Selhub, Bella Adler, Jaime Gofin, Joseph H. Abramson, Gideon Friedman, and Irwin H. Rosenberg A mildly to moderately elevated nonfasting total homocysteine level is a substantial risk marker for death from any cause. The association seems to be stronger during the first 5 years of follow-up.
Jacob Selhub, Paul F. Jacques, Irwin H. Rosenberg, Gail Rogers, Barbara A. Bowman, Elaine W. Gunter, Jacqueline D. Wright, and Clifford L. Johnson Upper reference limits for serum total homocysteine concentration increased with age and were higher for male participants than for female participants at all ages. In most cases, high homocysteine concentrations were associated with low serum vitamin levels.
Jerome I. Tokars, Susan T. Cookson, Margaret A. McArthur, Cindy L. Boyer, Allison J. McGeer, and William R. Jarvis Bloodstream infections seem to be infrequent among outpatients receiving infusions through central and midline catheters. However, the rate of infection increases with bone marrow transplantation, parenteral nutrition, infusion therapy in a hospital clinic or physician's office, and use of multilumen catheters.
Brief Communications
Wiam I. Hussein, Ralph Green, Donald W. Jacobsen, and Charles Faiman Hypothyroidism may be a treatable cause of hyperhomocysteinemia, and elevated plasma homocysteine levels may be an independent risk factor for the accelerated atherosclerosis seen in primary hypothyroidism.
Andrew G. Bostom, Irwin H. Rosenberg, Halit Silbershatz, Paul F. Jacques, Jacob Selhub, Ralph B. D'Agostino, Peter W.F. Wilson, and Philip A. Wolf Nonfasting total homocysteine levels are an independent risk factor for incident stroke in elderly persons.
Reviews
John W. Eikelboom, Eva Lonn, Jacques Genest, Jr., Graeme Hankey, and Salim Yusuf This paper reviews the relation between homocyst(e)ine levels and risk for cardiovascular disease and the potential cardiovascular risk reduction associated with therapy to decrease homocyst(e)ine levels.
Kishore J. Harjai Recent studies have identified several potential new cardiovascular risk factors, including left ventricular hypertrophy, homocysteinemia, lipoprotein(a) excess, hypertriglyceridemia, oxidative stress, and hyperfibrinogenemia. This review summarizes the current literature that supports these conditions as risk factors.
Editorials
Ian Graham Is an elevated plasma homocysteine level bad for you? Although the association between genetic hyperhomocysteinemia and vascular disease would clearly indicate that an increased homocysteine level precedes the disease, these issues have not been definitively resolved. Several papers in this issue address this topic.
David R. Goldmann The turn of the millennium will mark the end of the third year of the Medical Writings section in Annals. How successful has this section been, and what lies ahead for it?
Letters Dietary Vitamin A Intake and Risk for Hip Fracture
Vulnerable Plaque
Decrease in Endothelin-1 Plasma Levels during the Menstrual Cycle and after Ethinylestradiol Treatment
Correction: Cardiorespiratory Fitness, Impaired Fasting Glucose, and Type 2 Diabetes
Fitzhugh Mullan Richard Perry, MD, is a physician of the 20th century. He is effective, self-effacing, much loved—and embattled.
Neil S. Cherniack
Thomas L. Petty
Thomas McGinn
LouAnn Schraffenberger
George N. Braman
Melvyn Rubenfire The results of several studies published in 1998 were important to the practice of cardiology. The main areas of interest were evaluation of chest pain, acute coronary syndromes, valvular heart disease, congestive heart failure, and coronary risk factors. | ||||||||||||||||||||||||||||||||||||||||||||
In this Issue
Articles
Previous Issue